PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC

• Malaka Ameratunga,

  Affiliation Department of Medical Oncology, Austin Health, Olivia-Newton John Cancer and Wellness Centre, Victoria, Australia

  ⨯
• Khashayar Asadi,

  Affiliation Department of Pathology, Austin Health, Victoria, Australia

  ⨯
• Xihui Lin,

  Affiliation Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada

  ⨯
• Marzena Walkiewicz,

  Affiliation The Olivia Newton-John Cancer Research Institute, Victoria, Australia

  ⨯
• Carmel Murone,

  Affiliations Department of Pathology, Austin Health, Victoria, Australia, The Olivia Newton-John Cancer Research Institute, Victoria, Australia

  ⨯
• Simon Knight,

  Affiliation Department of Thoracics, Austin Health, Victoria, Australia

  ⨯
• Paul Mitchell,

  Affiliation Department of Medical Oncology, Austin Health, Olivia-Newton John Cancer and Wellness Centre, Victoria, Australia

  ⨯
• Paul Boutros,

  Affiliations Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada, Department of Medical Biophysics, University of Toronto, Toronto, Canada, Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada

  ⨯
• Thomas John

  * E-mail: tom.john@onjcri.org.au

  Affiliations Department of Medical Oncology, Austin Health, Olivia-Newton John Cancer and Wellness Centre, Victoria, Australia, The Olivia Newton-John Cancer Research Institute, Victoria, Australia, School of Cancer Medicine, La Trobe University, Victoria, Australia, University of Melbourne, Victoria, Australia

  ⨯